| Literature DB >> 31051106 |
María Isabel Hernández-Alvarez1, David Sebastián2, Sara Vives3, Saška Ivanova2, Paola Bartoccioni4, Pamela Kakimoto5, Natalia Plana3, Sónia R Veiga6, Vanessa Hernández3, Nuno Vasconcelos3, Gopal Peddinti7, Anna Adrover3, Mariona Jové8, Reinald Pamplona8, Isabel Gordaliza-Alaguero2, Enrique Calvo9, Noemí Cabré10, Rui Castro11, Antonija Kuzmanic3, Marie Boutant12, David Sala13, Tuulia Hyotylainen14, Matej Orešič15, Joana Fort16, Ekaitz Errasti-Murugarren3, Cecilia M P Rodrígues11, Modesto Orozco3, Jorge Joven10, Carles Cantó12, Manuel Palacin16, Sonia Fernández-Veledo17, Joan Vendrell18, Antonio Zorzano19.
Abstract
Non-alcoholic fatty liver is the most common liver disease worldwide. Here, we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver disease. Reduced Mfn2 expression was detected in liver biopsies from patients with non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2 levels were detected in mouse models of steatosis or NASH, and its re-expression in a NASH mouse model ameliorated the disease. Liver-specific ablation of Mfn2 in mice provoked inflammation, triglyceride accumulation, fibrosis, and liver cancer. We demonstrate that Mfn2 binds phosphatidylserine (PS) and can specifically extract PS into membrane domains, favoring PS transfer to mitochondria and mitochondrial phosphatidylethanolamine (PE) synthesis. Consequently, hepatic Mfn2 deficiency reduces PS transfer and phospholipid synthesis, leading to endoplasmic reticulum (ER) stress and the development of a NASH-like phenotype and liver cancer. Ablation of Mfn2 in liver reveals that disruption of ER-mitochondrial PS transfer is a new mechanism involved in the development of liver disease.Entities:
Keywords: MAMs; Mfn2; NASH; mitochondria; phosphatidylserine; phospholipid transfer
Mesh:
Substances:
Year: 2019 PMID: 31051106 DOI: 10.1016/j.cell.2019.04.010
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582